Evidence map›Paper›PMID 38532757›Full record

ArticleOxford medical case reports2024

A malignant spiradenoma of the forehead: a case report and literature review.

Mohamed Badie Ahmed, Khaled E Elzawawi, Ayda AlHammadi, Aysha Al-Malki, Mahir Petkar, Salim Al Lahham, Abeer Alsherawi

Open access · goldAbstract readCase Reports
In one paragraph

Article in Oxford medical case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mohamed Badie AhmedPlastic Surgery Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.ORCID https://orcid.org/0000-0001-8727-9101
Khaled E ElzawawiCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
Ayda AlHammadiDepartment of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar.
Aysha Al-MalkiDepartment of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar.
Mahir PetkarDepartment of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar.ORCID https://orcid.org/0000-0002-0297-8075
Salim Al LahhamPlastic Surgery Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Abeer AlsherawiPlastic Surgery Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Hamad General Hospital · QAHamad Medical Corporation · QAQatar University · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spiroadenomas, arising from sweat glands, are rare benign skin tumors primarily found as solitary nodules on the head, neck, and trunk. The malignant subtype, Spiradenocarcinoma (MSA), originating from benign spiradenomas, is extremely rare and occurs mainly in individuals over 50. MSA exhibits aggressiveness with higher metastasis rates and lower survival rates. Surgical excision is the standard management, supported by imaging modalities like MRI, CT-scan, and ultrasound. We present a 69-year-old female with a medical history of diabetes, hypertension, and dyslipidemia who presented in 2014 with multiple swellings on the forehead and left arm. Initial excisions revealed capillary hemangioma lesions. Subsequent visits involved the excision of further facial and body lesions, with some identified as intradermal nevi. In 2022, she presented to plastic surgery clinic with forehead swelling. The biopsy showed MSA lesion with involved margins. Thus, subsequent re-excision was carried out. One year later, she came with recurrent forehead swelling. Excision and direct closure of the lesion showed involvement of part of the subcutaneous tissue (fat globule) showing residual/recurrent MSA that is very close to nerve trunks. Malignant Spiradenomas (MSAs) usually arise from benign spiradenomas. Therefore, consideration is given to preemptive removal of these tumors due to their potential evolution. The primary treatment approach involves surgery, with a focus on wide local excision and a minimum margin of 1 cm to diminish the risk of metastasis. Vigilant follow-up is essential to promptly identify any recurrences or spreading.

Identifiers

PMID38532757
PMCPMC10962237
OpenAlexW4393146622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.